ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Molecular Instruments® Continues RNA Imaging Leadership with Next-Generation miRNA/siRNA Detection and Clinical-Grade Ready-to-Use Kits

Molecular Instruments® (MI), the inventor of the HCR™ platform, today announced key enhancements to its HCR™ Gold and HCR™ Pro product lines. These upgrades include next-generation chemistry for high-specificity detection of small RNA targets—including microRNAs (miRNAs) and small interfering RNAs (siRNAs)—and the introduction of a new ready-to-use, prefilled dispenser format for automated assay workflows.

Together, these advances represent a pivotal development in delivering clinical-grade RNA imaging performance with seamless, high-throughput usability.

Next-Generation HiFi Chemistry Unlocks Small RNA Detection

Both HCR™ Gold and HCR™ Pro now incorporate next-generation HCR™ HiFi architecture, enabling robust detection of small RNAs such as miRNA and siRNA with built-in automatic background suppression, allowing for unmatched signal-to-background performance. Researchers can now visualize and quantify low-abundance, short-length targets with the same confidence as typical transcripts—driving new biological insights across both foundational research and translational discovery.

Prefilled Dispensers Support Scalable, Clinical-Grade Performance

Additionally, MI has begun shipping HCR™ Pro kits in a fully prefilled dispenser format for the DISCOVERY ULTRA automated research platform. This ready-to-use packaging eliminates manual reagent preparation, streamlining setup and minimizing variability between users and runs. By simplifying the workflow and enhancing reproducibility, these prefilled kits mark a critical milestone on the path toward scalable, clinical-grade molecular imaging.

“These upgrades are a major step forward in our vision to make high-performance bioimaging effortless and with the highest levels of precision,” said Dr. Aneesh Acharya, Chief Commercial Officer at Molecular Instruments. “With small RNA detection and ready-to-use dispensers, HCR™ Pro and HCR™ Gold are setting a new standard for clinical-grade workflows.”

The prefilled format is now available for an initial automation platform, with broader compatibility in development.

To learn more or place an order, visit www.hcrimaging.com.

About Molecular Instruments

Molecular Instruments® (www.molecularinstruments.com) is a company powering the future of bioimaging through the development of clinical-grade molecular detection technologies. The company offers automated and manual chromogenic and fluorescent in situ hybridization (ISH) assays that seamlessly integrate with existing immunohistochemistry (IHC) and immunofluorescence (IF) workflows. With thousands of users globally, MI is establishing the field standard for RNA detection and supporting applications from academic research to drug development and diagnostics.

“With small RNA detection and ready-to-use dispensers, HCR™ Pro and HCR™ Gold are setting a new standard for clinical-grade workflows."

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  233.22
+4.06 (1.77%)
AAPL  278.85
+1.30 (0.47%)
AMD  217.53
+3.29 (1.54%)
BAC  53.65
+0.66 (1.25%)
GOOG  320.12
-0.16 (-0.05%)
META  647.95
+14.34 (2.26%)
MSFT  492.01
+6.51 (1.34%)
NVDA  177.00
-3.26 (-1.81%)
ORCL  201.95
-3.01 (-1.47%)
TSLA  430.17
+3.59 (0.84%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.